HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dajun Yang Selected Research

apogossypolone

9/2014Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy.
1/2011Apogossypolone targets mitochondria and light enhances its anticancer activity by stimulating generation of singlet oxygen and reactive oxygen species.
4/2010Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
9/2008Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.
2/2008Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dajun Yang Research Topics

Disease

31Neoplasms (Cancer)
07/2022 - 04/2003
6Nasopharyngeal Carcinoma
01/2018 - 11/2008
6Breast Neoplasms (Breast Cancer)
08/2009 - 10/2002
4Stomach Neoplasms (Stomach Cancer)
02/2016 - 11/2014
4Lymphoma (Lymphomas)
12/2009 - 02/2008
3Leukemia
01/2022 - 07/2007
3Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
10/2011 - 06/2008
3Pancreatic Neoplasms (Pancreatic Cancer)
05/2010 - 04/2010
3Prostatic Neoplasms (Prostate Cancer)
01/2007 - 05/2004
2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2022 - 01/2019
2Neoplasm Metastasis (Metastasis)
06/2017 - 09/2013
2Carcinogenesis
01/2015 - 05/2012
2Multiple Myeloma
08/2013 - 06/2008
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
12/2009 - 02/2008
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2022
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
01/2019
1Nasopharyngeal Neoplasms (Cancer of the Nasopharynx)
01/2018
1Hepatocellular Carcinoma (Hepatoma)
01/2018
1B-Cell Leukemia (Leukemia, B Cell)
08/2017
1Papillary Thyroid Cancer
06/2017
1Colonic Neoplasms (Colon Cancer)
01/2015
1Colorectal Neoplasms (Colorectal Cancer)
01/2011
1Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
04/2010
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
09/2008
1Non-Hodgkin Lymphoma (Lymphosarcoma)
09/2008
1B-Cell Lymphoma (Lymphoma, B Cell)
06/2008

Drug/Important Bio-Agent (IBA)

16Proteins (Proteins, Gene)FDA Link
01/2018 - 10/2002
6GossypolIBA
08/2013 - 07/2003
5apogossypoloneIBA
09/2014 - 02/2008
5Pharmaceutical PreparationsIBA
05/2012 - 07/2003
4Phosphotransferases (Kinase)IBA
01/2019 - 02/2006
3Inhibitor of Apoptosis ProteinsIBA
01/2018 - 04/2011
3LigandsIBA
01/2015 - 04/2003
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
05/2012 - 10/2002
3GemcitabineFDA Link
10/2011 - 04/2010
3MI 319IBA
05/2010 - 12/2009
2Tyrosine Kinase InhibitorsIBA
07/2022 - 01/2022
2olverembatinibIBA
01/2022 - 01/2019
2APG-1387IBA
01/2018 - 10/2016
2DNA (Deoxyribonucleic Acid)IBA
08/2013 - 04/2010
2Cisplatin (Platino)FDA LinkGeneric
04/2010 - 11/2008
2MI-219IBA
12/2009 - 03/2008
29-chloro-2-methylellipticinium acetateIBA
07/2007 - 01/2007
2PeptidomimeticsIBA
10/2003 - 07/2003
2Peptides (Polypeptides)IBA
08/2003 - 07/2003
1Aldehyde DehydrogenaseIBA
07/2022
1osimertinibIBA
07/2022
1Tetrazolium SaltsIBA
07/2022
1Carboplatin (JM8)FDA LinkGeneric
07/2022
1Paclitaxel (Taxol)FDA LinkGeneric
07/2022
1trametinibIBA
07/2022
1Drug CombinationsIBA
07/2022
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
07/2022
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
07/2022
1MitogensIBA
07/2022
1ErbB Receptors (EGF Receptor)IBA
07/2022
1LisaftoclaxIBA
01/2022
1STAT5 Transcription FactorIBA
01/2022
1Anaplastic Lymphoma KinaseIBA
11/2020
1pembrolizumabIBA
11/2019
1Immune Checkpoint InhibitorsIBA
11/2019
1Imatinib Mesylate (Gleevec)FDA Link
01/2019
1ponatinibIBA
01/2019
1Messenger RNA (mRNA)IBA
01/2018
1CaspasesIBA
01/2018
1IodineIBA
06/2017
1Wnt ProteinsIBA
01/2015
1ParaffinIBA
01/2015
1human ERBB2 proteinIBA
11/2014
1Acetates (Acetic Acid Esters)FDA Link
08/2013
1Antineoplastic Agents (Antineoplastics)IBA
08/2013
1houttuyninumIBA
05/2012
1ErbB-2 ReceptorIBA
05/2012
1Ribonucleotide Reductases (Ribonucleotide Reductase)IBA
10/2011
1N- benzhydryl- 5- (2- (methylamino)propanamido)- 3- (3- methylbutanoyl)- 6- oxodecahydropyrrolo(1,2- a)(1,5)diazocine- 8- carboxamideIBA
04/2011
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2011
1Sirtuin 1IBA
05/2010
1EnzymesIBA
04/2010
1Histones (Histone)IBA
04/2010
1ImmunosorbentsIBA
04/2010
1nutlin 3IBA
12/2009
1Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
09/2008
1Proteasome InhibitorsIBA
09/2008
1Bortezomib (Velcade)FDA Link
09/2008
1Proteasome Endopeptidase Complex (Proteasome)IBA
09/2008
1UbiquitinIBA
09/2008
1Etoposide (VP 16)FDA LinkGeneric
06/2008
1Therapeutic UsesIBA
06/2008
14-hydroxycyclophosphamideIBA
06/2008
1gossypol acetic acidIBA
06/2008
1Cytotoxins (Cytolysins)IBA
06/2008
1carfilzomibIBA
06/2008
1Doxorubicin (Adriamycin)FDA LinkGeneric
06/2008
1Neuregulin-1 (Neuregulin 1)IBA
07/2007

Therapy/Procedure

16Therapeutics
07/2022 - 06/2003
4Radiotherapy
09/2013 - 10/2003
2Immunotherapy
01/2022 - 01/2015
2Oral Administration
11/2020 - 05/2010
1Drug Therapy (Chemotherapy)
09/2013
1Aftercare (After-Treatment)
08/2013